Study guide
3.4 Chronotropic Infusion Therapies: Dopamine & Epinephrine
AHA ACLS Provider Advanced Cardiovascular Life Support
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: BLS & High-Quality CPR Foundation
1.1 Chest Compression Mechanics & Performance Metrics 1.2 Chest Compression Fraction & Interruptions 1.3 Two-Rescuer Rotation & Fatigue Prevention 1.4 AED Operation & Special Resuscitation Circumstances
2 Chapter 2: ACLS Adult Cardiac Arrest Algorithm
2.1 Cardiac Arrest Recognition & Systematic Approach 2.2 VF/pVT Management & Defibrillation Energy Protocols 2.3 Asystole & PEA Management 2.4 Epinephrine Dosing & Pharmacodynamics in Arrest 2.5 Antiarrhythmic Drugs: Amiodarone & Lidocaine in Refractory VF/pVT 2.6 Reversible Causes of Arrest: The H's 2.7 Reversible Causes of Arrest: The T's 2.8 Physiological Monitoring & CPR Quality Metrics
3 Chapter 3: Bradycardia Algorithm
3.1 Symptomatic Bradycardia Assessment & Instability Criteria 3.2 Atropine Dosing, Indications & Block Limitations 3.3 Transcutaneous Pacing (TCP) Operation & Management 3.4 Chronotropic Infusion Therapies: Dopamine & Epinephrine
4 Chapter 4: Tachycardia Algorithm
4.1 Tachycardia Triage: Stable vs. Unstable Assessment 4.2 Synchronized Cardioversion Indications, Energy Doses & Sync Mechanics 4.3 Stable Narrow-Complex Tachycardia: Vagal Maneuvers & Adenosine Protocol 4.4 Stable Wide-Complex Tachycardia & Antiarrhythmic Infusions 4.5 Polymorphic VT (Torsades de Pointes) & Magnesium Sulfate Protocol
5 Chapter 5: Acute Coronary Syndrome (ACS)
5.1 ACS Identification, EMS & ED Triage 5.2 Initial ED & Prehospital Pharmacotherapy 5.3 STEMI vs. NSTE-ACS Risk Stratification & Biomarkers 5.4 Reperfusion Strategies & Quality Benchmark Time Goals
6 Chapter 6: Acute Ischemic Stroke
6.1 Stroke Recognition & Out-of-Hospital Assessment 6.2 Emergency Department Evaluation & Diagnostic Time Goals 6.3 Fibrinolytic Therapy & Blood Pressure Management 6.4 Endovascular Therapy (EVT) & Post-Acute Care
7 Chapter 7: Post–Cardiac Arrest Care
7.1 Immediate Post-ROSC Airway & Respiratory Optimization 7.2 Hemodynamic Management & MAP Optimization 7.3 Temperature Control & Targeted Temperature Management (TTM) 7.4 Emergent Coronary Angiography & Multimodal Neuroprognostication
8 Chapter 8: Airway Management & Pharmacology
8.1 Basic Airway Adjuncts & Bag-Mask Ventilation 8.2 Advanced Airways: Supraglottic Devices & Endotracheal Intubation 8.3 Continuous Waveform Capnography 8.4 ACLS Emergency Drug Reference & Administration Routes
9 Chapter 9: High-Performance Team Dynamics & Special Circumstances
9.1 High-Performance Team Dynamics & Communication 9.2 Resuscitation Debriefing & Quality Improvement Metrics 9.3 Special Arrest Circumstances: Cardiac Arrest in Pregnancy 9.4 Special Arrest Circumstances: Opioids, Anaphylaxis, Drowning & Hypothermia
3.4 Chronotropic Infusion Therapies: Dopamine & Epinephrine
Key Takeaways Explain This Topic AI
Chronotropic infusions are second-line treatments when Atropine fails or is contraindicated, or when TCP is unavailable or ineffective.
Dopamine is infused at 5 to 20 mcg/kg/min and titrated to patient response, exerting dose-dependent beta-1 (inotropic/chronotropic) and alpha-1 (vasopressor) stimulation.
Epinephrine is infused at 2 to 10 mcg/min (non-weight-based in adult ACLS) as a potent alpha and beta-1 adrenergic agonist.
Both medications increase heart rate, contractility, and blood pressure, requiring careful monitoring to avoid ischemia and dysrhythmias.
Last updated: July 2026
- 3.4 Chronotropic Infusion Therapies: Dopamine & Epinephrine
- Indications for Chronotropic Infusions
Chronotropic IV infusions serve as an essential second-line pharmacological therapy in the management of symptomatic bradycardia. These infusions are indicated when the primary treatment with Atropine has proven ineffective, or when the patient has reached the maximum cumulative dose of 3 mg of Atropine without clinical improvement. Furthermore, chronotropic infusions are utilized when transcutaneous pacing (TCP) is either unavailable, delayed, or failing to achieve mechanical capture. In some clinical scenarios, particularly when a patient is hypotensive, an infusion may be preferred over TCP as a bridge to a permanent transvenous pacemaker, especially if the patient cannot tolerate the discomfort of transcutaneous pacing. The two primary medications recommended by the AHA ACLS guidelines for this purpose are Dopamine and Epinephrine.
Dopamine Infusion
Dopamine is a naturally occurring catecholamine that acts as a precursor to norepinephrine. Its cardiovascular effects are highly dose-dependent, making it a versatile but complex medication to administer. In the context of the bradycardia algorithm, Dopamine is utilized for its combined chronotropic (heart rate-increasing) and inotropic (contractility-increasing) properties.
Dosing and Titration
The recommended dosing for a Dopamine infusion in symptomatic bradycardia is 5 to 20 micrograms per kilogram per minute (mcg/kg/min).
At lower to moderate doses (typically 5 to 10 mcg/kg/min), Dopamine primarily stimulates beta-1 adrenergic receptors in the heart. This stimulation increases both the heart rate and the force of myocardial contraction, thereby improving cardiac output.
As the dose is titrated upward (10 to 20 mcg/kg/min), Dopamine begins to strongly stimulate alpha-1 adrenergic receptors in the peripheral vasculature. This results in profound peripheral vasoconstriction, which significantly increases systemic vascular resistance and elevates blood pressure.
The key to Dopamine administration is careful titration based on the patient's clinical response. The provider must continuously monitor the heart rate and blood pressure, adjusting the infusion rate to achieve the desired hemodynamic stability while avoiding excessive tachycardia or hypertension.
Epinephrine Infusion
Epinephrine is a potent, non-selective adrenergic agonist that vigorously stimulates both alpha and beta receptors. It is a highly effective alternative to Dopamine for the treatment of symptomatic bradycardia, particularly in patients who are severely hypotensive or in whom Dopamine has failed to elicit an adequate response.
Dosing and Titration
The recommended dosing for an Epinephrine infusion in the bradycardia algorithm is 2 to 10 micrograms per minute (mcg/min). It is crucial to note that, unlike Dopamine, Epinephrine dosing for bradycardia is typically not weight-based in the adult algorithm.
Epinephrine's profound beta-1 adrenergic stimulation directly increases the heart rate and contractility, rapidly improving cardiac output. Concurrently, its alpha-adrenergic effects cause robust vasoconstriction, which supports blood pressure and improves coronary and cerebral perfusion pressures. The infusion should be initiated at a low rate (e.g., 2 mcg/min) and titrated upwards slowly, monitoring the patient's physiological response.
Mechanisms of Beta-1 Adrenergic Stimulation
Both Dopamine and Epinephrine exert their primary chronotropic effects through the stimulation of beta-1 adrenergic receptors located predominantly in the myocardium and the conduction system (specifically the SA and AV nodes). When these receptors are stimulated, a cascade of intracellular events leads to an increase in intracellular calcium. This influx of calcium accelerates the rate of spontaneous depolarization in the pacemaker cells, resulting in a faster heart rate (positive chronotropy). Additionally, the increased calcium availability enhances the force of myocardial contraction (positive inotropy) and increases the speed of electrical conduction through the AV node (positive dromotropy). This triad of effects makes beta-1 agonists exceptionally effective at reversing the hemodynamic compromise associated with symptomatic bradycardia.
Hemodynamic Monitoring and Precautions
The administration of continuous chronotropic infusions requires rigorous and continuous hemodynamic monitoring. Patients receiving Dopamine or Epinephrine infusions must be placed on continuous cardiac telemetry to monitor for rate and rhythm changes. Invasive blood pressure monitoring via an arterial line is highly recommended, though non-invasive blood pressure (NIBP) monitoring cycling every few minutes may be used initially.
Providers must be acutely aware of the potential adverse effects associated with these potent medications. Excessive beta-1 stimulation can lead to severe tachycardia, which dramatically increases myocardial oxygen demand and can precipitate myocardial ischemia or infarction. Furthermore, catecholamine infusions can irritate the myocardium, increasing the risk of potentially lethal ventricular dysrhythmias, such as premature ventricular contractions (PVCs), ventricular tachycardia, or ventricular fibrillation. Therefore, the goal of therapy is always to use the lowest effective dose required to maintain adequate perfusion and resolve symptoms, rather than aiming for a specific, normalized heart rate. Careful titration, constant vigilance, and readiness to manage complications are the hallmarks of safe chronotropic infusion therapy.